#USA #San Diego #Class Action #ImmunityBio #IBRX

Class Action Overview

ImmunityBio, Inc. has recently made headlines as investors grapple with substantial financial losses due to misleading statements concerning the company’s lead product, Anktiva. A law firm, Robbins Geller Rudman & Dowd LLP, has announced that individuals who acquired ImmunityBio’s securities from January 19, 2026, to March 24, 2026, are encouraged to step forward and seek lead plaintiff status in a class action lawsuit against the biotechnology giant. This lawsuit aims to address potential violations of the Securities Exchange Act of 1934, specifically involving ImmunityBio and its Executive Chairman.

Allegations Against ImmunityBio

The class action suit has been sparked by allegations that the company provided false and misleading statements regarding its product, Anktiva, which is marketed as an innovative cancer treatment. Key assertions within the complaint claim that during the class period, executives misrepresented Anktiva’s effectiveness, specifically the efficacy of the drug in making non-muscle invasive bladder cancer (NMIBC) patients free from cancer long-term, a claim that lacks verified evidence.

Furthermore, ImmunityBio is accused of labeling Anktiva as a cancer vaccine, which the lawsuit declares as misleading. Critically, the allegations state that Dr. Patrick Soon-Shiong, the Executive Chairman and Global Scientific and Medical Officer of ImmunityBio, significantly exaggerated the product's capabilities.

FDA Warning and Market Response

Complicating matters further, on March 24, 2026, news broke regarding a stern warning letter from the U.S. Food and Drug Administration (FDA) addressed to ImmunityBio's CEO, Richard Adcock. The FDA criticized the company for misbranding Anktiva through promotional communications that created false impressions of its effectiveness, suggesting it could cure and prevent all types of cancer. This revelation led to a drastic 21% drop in ImmunityBio's stock, leaving investors facing dire circumstances.

The Role of Lead Plaintiff

Under the Private Securities Litigation Reform Act of 1995, any investor who acquired ImmunityBio securities during the specified period has the legal standing to apply for the role of lead plaintiff in this lawsuit. The lead plaintiff is typically the individual with the most significant financial interest in the case and serves to represent the entire class of investors. They have the authority to choose their legal representatives and will actively guide the lawsuit’s direction.

This role is critical, as it helps ensure that the concerns of all affected investors are taken seriously and that they collectively pursue justice and any potential recovery of their losses.

About Robbins Geller

Robbins Geller Rudman & Dowd LLP stands as a leading force in securities fraud prosecution, having successfully represented investors for years. The firm achieved a remarkable milestone by recovering over $916 million for investors in 2025 alone, a testament to their effectiveness in holding corporations accountable for fraudulent behavior.

Conclusion

Investors who experienced significant losses from their investments in ImmunityBio during the class period are urged to consider stepping forward. Those interested can submit their details through the law firm's website or contact the attorneys directly for further assistance. The class action presents an invaluable opportunity for affected individuals to reclaim losses and seek justice.

To learn more about the ImmunityBio class action lawsuit or decide on participating, please visit Robbins Geller's website.

For additional inquiries, interested parties can reach attorneys Ken Dolitsky or Michael Albert at 800/449-4900 or via email at [email protected].